Monthly Archives: May 2011

Getting IT Together: Empowering the Patient with Health Information

By Jennifer Ringler | Published: May 4, 2011
Tasked with encouraging the widespread exchange of online health information, the new National eHealth Collaborative (NeHC) Consumer Consortium needs to hit the ground running, as CEO Kate Berry tells Jennifer Ringler. To put health IT in the hands of patients, to foster more open communication between patients and physicians, to promote better health and wellness (and [...]
Posted in Medical Education, Patient Communication, patient education | Tagged , , , , | Leave a comment

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

By Ben Comer | Published: May 4, 2011
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Posted in Deals, Strategy | Tagged , , , , | 3 Comments

Did Digital Marketers Forget That Docs Write the Scripts?

By Ben Comer | Published: May 4, 2011
Consumer drug marketing online is way smarter and more sophisticated than healthcare professional (HCP) efforts, with dollars continuing to favor sales forces over digital executions, according to L2’s Digital IQ index. Of the 70 brands assessed in the report, well over half were classified as “challenged” or “feeble” with respect to online and mobile prowess. The [...]
Posted in Advertising, E-Media, Marketing, Strategy, Technology, social media | Tagged , , | 1 Comment

Seeing Through the EU Transparency Directive

By Guest Blogger | Published: May 4, 2011
Reflector outlines why the EU’s so-called “transparency directive” has not set the industry on fire. For such a big subject, it is receiving little public attention. No matter how much pharma executives eulogise the heady prospects for personalised medicine or the protean potential of pharmacogenomics, everything all comes down, at the end of the day, to money. [...]
Posted in Europe, Global, Guest Blog, Regulatory, pricing | Tagged , , , | Leave a comment